PL4108259T3 - Sposób zatężania przeciwciał i ich produkty terapeutyczne - Google Patents

Sposób zatężania przeciwciał i ich produkty terapeutyczne

Info

Publication number
PL4108259T3
PL4108259T3 PL22178117.2T PL22178117T PL4108259T3 PL 4108259 T3 PL4108259 T3 PL 4108259T3 PL 22178117 T PL22178117 T PL 22178117T PL 4108259 T3 PL4108259 T3 PL 4108259T3
Authority
PL
Poland
Prior art keywords
antibodies
concentration
therapeutic products
therapeutic
products
Prior art date
Application number
PL22178117.2T
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech, Inc.
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4108259(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc., Novartis Ag filed Critical Genentech, Inc.
Publication of PL4108259T3 publication Critical patent/PL4108259T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
PL22178117.2T 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne PL4108259T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof

Publications (1)

Publication Number Publication Date
PL4108259T3 true PL4108259T3 (pl) 2024-05-13

Family

ID=35996499

Family Applications (5)

Application Number Title Priority Date Filing Date
PL22178156.0T PL4104859T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL22178117.2T PL4108259T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL20200642.5T PL3805248T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL10009914.2T PL2292636T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL05806393T PL1786830T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty lecznicze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL22178156.0T PL4104859T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL20200642.5T PL3805248T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL10009914.2T PL2292636T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty terapeutyczne
PL05806393T PL1786830T3 (pl) 2004-09-09 2005-09-08 Sposób zatężania przeciwciał i ich produkty lecznicze

Country Status (32)

Country Link
US (6) US20060051347A1 (pl)
EP (5) EP1786830B1 (pl)
JP (2) JP5210633B2 (pl)
KR (2) KR20070109975A (pl)
CN (3) CN102911268A (pl)
AR (1) AR050641A1 (pl)
AU (1) AU2005285243C1 (pl)
BR (1) BRPI0515649B8 (pl)
CA (1) CA2577317C (pl)
DK (5) DK1786830T3 (pl)
EC (1) ECSP077282A (pl)
ES (5) ES2528541T3 (pl)
FI (4) FI4108259T3 (pl)
GT (1) GT200500254A (pl)
HU (4) HUE065025T2 (pl)
IL (2) IL181372A (pl)
LT (4) LT4104859T (pl)
MA (1) MA28991B1 (pl)
MX (2) MX2007002812A (pl)
MY (2) MY162525A (pl)
NO (1) NO333660B1 (pl)
NZ (1) NZ553239A (pl)
PE (1) PE20060816A1 (pl)
PL (5) PL4104859T3 (pl)
PT (5) PT4108259T (pl)
RU (1) RU2390524C2 (pl)
SG (1) SG177161A1 (pl)
SI (5) SI4104859T1 (pl)
TN (1) TNSN07069A1 (pl)
TW (1) TWI372630B (pl)
WO (1) WO2006031560A2 (pl)
ZA (1) ZA200701626B (pl)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
DK2072040T3 (da) 2004-05-12 2013-07-29 Baxter Healthcare Sa Terapeutisk anvendelse af nukleinsyremikrokugler
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
EP2007506B1 (en) * 2006-03-31 2014-03-19 Danisco US Inc. Tangential flow filtration apparatuses, systems, and processes for the separation of compounds
ES2928096T3 (es) 2006-04-04 2022-11-15 Takeda Pharmaceuticals Co Un proceso para la concentración de un polipéptido
CA2681752A1 (en) * 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR101215740B1 (ko) 2007-07-17 2012-12-27 루드비히-막시밀리안스-우니버지테트 뮌헨 가변적 접선류 여과
WO2009068282A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
ES2406029T3 (es) * 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
WO2009139624A1 (en) * 2008-05-15 2009-11-19 Mucovax Holding B.V. Process for producing milk fractions rich in secretory immunoglobulins
JP2012511531A (ja) * 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
CA2750263C (en) * 2009-01-21 2018-03-20 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
US9586180B2 (en) * 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
MX2011012576A (es) * 2009-05-27 2012-05-08 Baxter Int Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.
US8822655B2 (en) 2009-09-29 2014-09-02 Hoffmann-La Roche Inc. Pre-filtration adjustment of buffer solutes
WO2011039274A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Multistep final filtration
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
ES2625511T3 (es) 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Métodos para la purificación de arylsulfatasa A
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2938357A1 (en) * 2012-12-28 2015-11-04 Novo Nordisk A/S High temperature dead end antibody filtration
AU2014205441B2 (en) 2013-01-09 2019-12-12 Takeda Pharmaceutical Company Limited Methods for purification of arylsulfatase A
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
CA3140009C (en) 2014-05-13 2023-09-05 Amgen Inc. Process control systems and methods for use with filters and filtration processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
US10550148B2 (en) * 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
JP6339674B2 (ja) 2014-06-25 2018-06-06 イー・エム・デイー・ミリポア・コーポレイシヨン 小型スパイラル型フィルターエレメント、モジュール、およびシステム
US10350518B2 (en) 2014-08-29 2019-07-16 Emd Millipore Corporation Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
KR102079585B1 (ko) 2014-08-29 2020-02-21 이엠디 밀리포어 코포레이션 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
ES2825704T3 (es) 2014-12-03 2021-05-17 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US20230134160A1 (en) * 2015-09-22 2023-05-04 Pfizer Inc. Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
ES2925059T3 (es) 2016-06-09 2022-10-13 Emd Millipore Corp Elementos de filtro de trayectoria radial, sistemas y métodos de uso de los mismos
KR102465761B1 (ko) * 2016-08-16 2022-11-09 젠자임 코포레이션 재조합 치료 단백질을 포함하는 유체의 처리 방법 및 상기 유체의 용도
SG11201901081XA (en) * 2016-08-17 2019-03-28 Boehringer Ingelheim Int Process for the preparation of highly concentrated liquid formulations containing biomolecules
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법
KR102791798B1 (ko) * 2018-04-12 2025-04-07 암젠 인크 안정한 단백질 조성물의 제조 방법
TWI846694B (zh) * 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
MX2021001554A (es) * 2018-08-10 2021-04-13 Amgen Inc Metodo de preparacion de una formulacion farmaceutica de anticuerpos.
KR102893280B1 (ko) * 2018-08-14 2025-12-01 브리스톨-마이어스 스큅 컴퍼니 개선된 단백질 회수
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
JP2022520793A (ja) * 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス
HUE056569T2 (hu) * 2019-07-31 2022-02-28 Catalent Uk Swindon Zydis Ltd Sûrûség-áramlásmérõ gyógyászati készítmény adagolásához
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
US20230374064A1 (en) * 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
KR20230108301A (ko) 2020-11-23 2023-07-18 아벡, 아이엔씨. 여과 시스템, 구성요소 및 방법
CA3210568A1 (en) * 2021-03-08 2022-09-15 Boehringer Ingelheim International Gmbh Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
JP2025507625A (ja) 2022-02-25 2025-03-21 アムジエン・インコーポレーテツド 高濃度の液体原薬を調製する方法
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
JP2025522984A (ja) * 2022-07-12 2025-07-17 ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 限外濾過／透析濾過（ｕｆ／ｄｆ）による高濃縮ｐｄ－１抗体溶液の調製方法
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
AU2024260197A1 (en) * 2023-04-25 2025-11-13 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (pl) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA847349B (en) * 1983-10-05 1985-04-24 Solco Basel Ag Process for the preparation of a biologically active extract
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU4803890A (en) 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
KR20010030665A (ko) * 1997-09-22 2001-04-16 세프라겐 코포레이션 유장 단백질의 순차적 분리법 및 그의 제제
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001003515A1 (en) 1999-07-07 2001-01-18 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
US8632778B2 (en) * 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
ES2351786T3 (es) * 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
CA2504134C (en) * 2002-11-01 2012-03-06 Bayer Healthcare Llc Process for concentration of macromolecules
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
CA2516836A1 (en) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
US20080247991A1 (en) 2004-02-26 2008-10-09 Trout Bernhardt L Solution Additives For the Attenuation of Protein Aggregation
US8471757B2 (en) 2004-08-19 2013-06-25 Electronic Navigation Research Institute, An Independent Administrative Institution Device using dielectric lens
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
US11220362B2 (en) 2017-08-16 2022-01-11 O & M Halyard, Inc. Method and system for wrapping ties in a facemask manufacturing process

Also Published As

Publication number Publication date
US11767370B2 (en) 2023-09-26
KR101528970B9 (ko) 2022-12-09
AU2005285243B2 (en) 2012-03-08
MX342788B (es) 2016-10-12
HUE067296T2 (hu) 2024-10-28
EP2292636B9 (en) 2024-01-03
CN102911268A (zh) 2013-02-06
EP2292636B1 (en) 2023-10-18
EP4104859A1 (en) 2022-12-21
US12371510B2 (en) 2025-07-29
JP2008512473A (ja) 2008-04-24
FI4104859T3 (fi) 2024-07-16
ES2942574T3 (es) 2023-06-02
JP5210633B2 (ja) 2013-06-12
PT1786830E (pt) 2015-02-05
SI2292636T1 (sl) 2024-02-29
MA28991B1 (fr) 2007-11-01
JP2012097086A (ja) 2012-05-24
US20230074486A1 (en) 2023-03-09
SI3805248T1 (sl) 2023-05-31
EP1786830A2 (en) 2007-05-23
SI1786830T1 (sl) 2015-03-31
BRPI0515649B1 (pt) 2021-10-13
DK4104859T3 (da) 2024-07-08
CA2577317C (en) 2016-04-26
AU2005285243A1 (en) 2006-03-23
ZA200701626B (en) 2008-10-29
ECSP077282A (es) 2007-03-29
LT4108259T (lt) 2024-04-10
US20060051347A1 (en) 2006-03-09
PE20060816A1 (es) 2006-09-02
PL1786830T3 (pl) 2015-05-29
HUE061899T2 (hu) 2023-08-28
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
US20140370003A1 (en) 2014-12-18
ES2528541T3 (es) 2015-02-10
US20070237762A1 (en) 2007-10-11
FI3805248T3 (fi) 2023-04-21
HUE065025T2 (hu) 2024-04-28
BRPI0515649B8 (pt) 2021-11-03
HK1101249A1 (en) 2007-10-12
PT4108259T (pt) 2024-03-07
MX2007002812A (es) 2007-05-16
IL181372A (en) 2012-01-31
AR050641A1 (es) 2006-11-08
MY162525A (en) 2017-06-15
NO333660B1 (no) 2013-08-05
EP2292636A3 (en) 2013-05-01
BRPI0515649A (pt) 2008-07-29
PL2292636T3 (pl) 2024-03-11
TW200612989A (en) 2006-05-01
DK4108259T3 (da) 2024-03-11
ES2975166T3 (es) 2024-07-03
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
NZ553239A (en) 2009-11-27
DK1786830T3 (en) 2015-01-19
WO2006031560A3 (en) 2006-08-24
FI2292636T3 (fi) 2024-01-12
US20090214522A1 (en) 2009-08-27
KR20070109975A (ko) 2007-11-15
EP3805248A3 (en) 2021-07-14
MY150549A (en) 2014-01-30
CN104961797B (zh) 2020-12-25
SI4108259T1 (sl) 2024-04-30
PL4104859T3 (pl) 2024-08-26
LT4104859T (lt) 2024-07-10
FI4108259T3 (fi) 2024-09-10
KR20120135530A (ko) 2012-12-14
CN104961797A (zh) 2015-10-07
PT3805248T (pt) 2023-04-05
PT4104859T (pt) 2024-07-02
DK3805248T3 (da) 2023-04-03
DK2292636T3 (da) 2024-01-15
HK1215869A1 (zh) 2016-09-23
SI4104859T1 (sl) 2024-08-30
CN101056885B (zh) 2015-08-26
PL3805248T3 (pl) 2023-05-22
SG177161A1 (en) 2012-01-30
TNSN07069A1 (en) 2008-06-02
IL181372A0 (en) 2007-07-04
IL216851A0 (en) 2012-01-31
KR101528970B1 (ko) 2015-06-15
US10370456B2 (en) 2019-08-06
LT3805248T (lt) 2023-04-25
RU2390524C2 (ru) 2010-05-27
EP4108259A1 (en) 2022-12-28
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
DK3805248T5 (da) 2023-04-24
NO20071432L (no) 2007-03-16
EP2292636A2 (en) 2011-03-09
JP5426641B2 (ja) 2014-02-26
EP3805248B1 (en) 2023-01-18
WO2006031560A2 (en) 2006-03-23
AU2005285243C1 (en) 2012-10-25
EP4108259B1 (en) 2024-01-03
EP1786830B1 (en) 2014-11-12
CN101056885A (zh) 2007-10-17
CA2577317A1 (en) 2006-03-23
HUE067662T2 (hu) 2024-11-28
TWI372630B (en) 2012-09-21
ES2983099T3 (es) 2024-10-22
EP4104859B1 (en) 2024-04-17
ES2968070T3 (es) 2024-05-07

Similar Documents

Publication Publication Date Title
TWI372630B (en) Process for concentration of antibodies and therapeutic products thereof
ZA200808865B (en) Antibody composition and methods for treatment of neoplastic disease
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
EP1814967A4 (en) APPARATUS FOR THERMOTRATING PARTICULATE MATERIALS
IL178593A (en) Specific antibodies of fcγriib and methods for their use
GB0521942D0 (en) Methods and software for analysis of research publications
ZA200703013B (en) Apparatus for heat treatment of particulate materials
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP1815226A4 (en) DEVICE AND METHOD FOR PURIFYING BIOLOGICAL SUBSTANCES
GB2445651B (en) Well treatment products and methods of using them
EP1740692A4 (en) METHOD AND DEVICE FOR QUANTITATIVE ASSAYS
IL183702A0 (en) Difluoronucleosides and process for preparation thereof
PT1919290E (pt) Métodos e produtos para tratamento de doenças
EP1767565A4 (en) PROCESS FOR CLEANING OLIGOANILINES AND OLIGOANILINES
ZA200607471B (en) Materials and methods for treatment of allergic disease
GB0400394D0 (en) Biosensor and method of manufacture
ZA200704725B (en) Product and method of treatment
IL179209A0 (en) Small molecules for treatment of hypercholesterolemia and related diseases
GB0515649D0 (en) Method and apparatus for treatment of preforms
ZA200703614B (en) Novel composition and methods for the treatment of immune related diseases